| 以肝星状细胞为靶标的抗肝纤维化治疗进展 |
| |
| 引用本文： | 张绪富,吕志平,刘晓燕.以肝星状细胞为靶标的抗肝纤维化治疗进展[J].中国药理学通报,2003,19(6):622-626. |
| |
| 作者姓名： | 张绪富 吕志平 刘晓燕 |
| |
| 作者单位： | 第一军医大学中医系,广州,510515 |
| |
| 基金项目： | 国家自然科学基金,No 30271627，广东省自然科学基金,No 020337 |
| |
| 摘 要： | 任何病因导致的慢性肝损伤,均可发展为肝纤维化。损伤肝脏的纤维化形成过程中,活化肝星状细胞(HSC)是主要细胞类型,并有重要细胞因子参与。目前治疗都以阻止活化HSC在损伤部位聚集和细胞外基质沉积为目标。该文就以HSC为靶标的抗肝纤维化最新治疗方案作一综述。
|
| 关 键 词： | 肝星状细胞 抗肝纤维化治疗 肝纤维化 |
| 文章编号： | 1001-1978(2003)06-0622-05 |
| 修稿时间： | 2002年9月18日 |
The progression for the therapy of liver fibrosis targeting to hepatic stellate cells |
| |
| ZHANG Xu-Fu,LU Zhi-Ping,LIU Xiao-Yan.The progression for the therapy of liver fibrosis targeting to hepatic stellate cells[J].Chinese Pharmacological Bulletin,2003,19(6):622-626. |
| |
| Authors: | ZHANG Xu-Fu LU Zhi-Ping LIU Xiao-Yan |
| |
| Abstract: | Following chronic liver injury of any etiology, there is progressive fibrosis. The identification of activated hepatic stellate cells(HSCs) as the major fibrogenic cell type in the injury liver, as well as the recognition of key cytokines involved in this process, has facilitated the design of promising new antifibrotic therapies. These therapies aimed at inhibiting the accumulation of activated HSCs at the cites of liver injury and preventing the deposition of extracellular matrix. This review describes the current therapeutic approaches for liver fibro-sis, with hepatic stellate cells as a target. |
| |
| Keywords: | hepatic stellate cells antifibrotic therapy liver fibrosis |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
